Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma

INTRODUCTION: The glioblastoma (GBM) immune microenvironment is highly suppressive as it targets and hinders multiple components of the immune system. Checkpoint blockade (CB) is being evaluated for GBM patients. However, biomarker analyses suggest that CB monotherapy may be effective only in a smal...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Garzon-Muvdi, Tomas, Theodros, Debebe, Luksik, Andrew S., Maxwell, Russell, Kim, Eileen, Jackson, Christopher M., Belcaid, Zineb, Ganguly, Sudipto, Tyler, Betty, Brem, Henry, Pardoll, Drew M., Lim, Michael
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5945499/
https://ncbi.nlm.nih.gov/pubmed/29755681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25061
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items